Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Co.'s U.S. Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. We show 31 historical shares outstanding datapoints in our DARE shares outstanding history coverage, used to compute DARE market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing DARE market cap history over the course of time is important for investors
interested in comparing DARE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of DARE versus a peer is one thing; comparing
DARE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like DARE can fluctuate over the course of history.
With this page we aim to empower investors researching DARE by allowing them to research the DARE market cap history. |
Free DARE Email Alerts:
Video: The Importance of Market Cap
